
Comprehensive Alpha and Beta Thalassemia Gene Panel







The Comprehensive Alpha and Beta Thalassemia Gene Panel is a group of blood tests that detects mutations in the alpha (HBA1, HBA2) and beta (HBB) globin genes responsible for thalassemia (an inherited blood disorder). This test helps accurately diagnose different forms of thalassemia, identify carriers, and guide treatment and family planning decisions.









Understanding Comprehensive Alpha and Beta Thalassemia Gene Panel
Thalassemia is an inherited blood disorder that affects the body’s ability to produce normal hemoglobin, the protein in red blood cells that carries oxygen. When hemoglobin production is reduced or abnormal, it can cause anemia and related symptoms like fatigue, weakness, pale skin, and shortness of breath.
The Comprehensive Alpha and Beta Thalassemia Gene Panel uses advanced Next-Generation Sequencing (NGS) technology to analyze the genes HBA1, HBA2, and HBB, which are responsible for producing the alpha and beta globin chains of hemoglobin.
This panel detects a wide range of genetic abnormalities, including point mutations, deletions, and insertions, that can cause alpha or beta thalassemia. Sequencing both sets of globin genes provides a complete genetic profile that helps confirm the diagnosis, identify carriers, and assess the risk of passing the condition to future generations.
Doctors may recommend this panel when there are symptoms such as moderate to severe anemia, persistent fatigue, pale or cold skin, shortness of breath, or irregular heartbeat. It is also advised for individuals with a family history of thalassemia or other hemoglobin disorders, known carriers of thalassemia traits, or children of carrier parents. This test helps diagnose thalassemia caused by abnormal hemoglobin production, detect underlying genetic mutations, and screen close relatives of affected patients to enable early diagnosis, appropriate management, and genetic counseling.
For this test, it is important to submit the clinical history, histopathology report, previous test results, and a doctor’s prescription at the time of sample collection. The Tata 1mg consolidated Test Requisition Form (TRF) must also be duly filled and submitted.
Lab test results may vary across different laboratories. Abnormal test results require an expert interpretation. Therefore, never try to self-medicate at home based solely on these results, and always consult a doctor for a proper understanding of the test results.
Note: Genetic counseling can be provided. If interested, please send the request to this email id: [email protected]
What does Comprehensive Alpha and Beta Thalassemia Gene Panel measure?
The Comprehensive Alpha and Beta Thalassemia Gene Panel measures genetic variants in the HBA1, HBA2, and HBB genes using Next-Generation Sequencing (NGS).
- Alpha Globin Genes (HBA1, HBA2): Detects deletions or mutations causing alpha thalassemia.
- Beta Globin Gene (HBB): Identifies mutations responsible for beta thalassemia.
- NGS Analysis: Provides high-resolution sequencing for accurate detection of point mutations, small deletions, or insertions.
By analyzing these genes together, the test offers a comprehensive understanding of the molecular causes of thalassemia, helping doctors confirm the diagnosis, determine disease type and severity, identify carriers, and plan appropriate management and genetic counseling.





FAQs related to Comprehensive Alpha and Beta Thalassemia Gene Panel
- Harewood J, Azevedo AM. Alpha Thalassemia. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from:
- Tamary H, Dgany O. Alpha-Thalassemia. 2005 Nov 1 [Updated 2024 May 23]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from:
- Needs T, Gonzalez-Mosquera LF, Lynch DT. Beta Thalassemia. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from:
- Langer AL. Beta-Thalassemia. 2000 Sep 28 [Updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from:
- National Center for Biotechnology Information (US). Genes and Disease [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 1998-. Thalassemia. Available from:
- Suhaimi SA, Zulkipli IN, Ghani H, Abdul-Hamid MRW. Applications of next generation sequencing in the screening and diagnosis of thalassemia: A mini-review. Front Pediatr. 2022 Sep 29;10:1015769. [Accessed 17 Oct. 2025]. Available from:
Other tests
- CBC (Complete Blood Count)
- FBS (Fasting Blood Sugar)
- Thyroid Profile Total (T3, T4 & TSH)
- HbA1c (Glycosylated Hemoglobin)
- PPBS (Postprandial Blood Sugar)
- Lipid Profile
- Vitamin D (25-Hydroxy)
- Urine R/M (Urine Routine & Microscopy)
- Coronavirus Covid -19 test- RT PCR
- LFT (Liver Function Test)
- KFT (Kidney Function Test)
- TSH (Thyroid Stimulating Hormone) Ultrasensitive
- ESR (Erythrocyte Sedimentation Rate)
- Uric Acid, Serum
- Vitamin B12
- CRP (C-Reactive Protein), Quantitative
- Urine C/S (Urine Culture and Sensitivity)
- Serum Electrolytes
- Serum Calcium
- Serum Creatinine
- Diabetes Screening (HbA1C & Fasting Sugar)
- KFT with Electrolytes (Kidney Function Test with Electrolytes)
- Cholesterol - Total
- Hb (Hemoglobin)
- Complete Hemogram (CBC & ESR)














